| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 06/03/2008 | US7381790 Copolymers for suppression of autoimmune diseases, and methods of use |
| 06/03/2008 | US7381731 Pharmaceutical composition comprising citrulline |
| 06/03/2008 | US7381713 Treatment of cancer by reduction of intracellular energy and pyrimidines |
| 06/03/2008 | US7381711 Substances for preventing and treating autoimmune diseases |
| 06/03/2008 | US7381710 Nucleic acid comprising a sequence encoding promyelocytic leukemia retinoic acid receptor alpha and a non-immunosuppressive inducer of tumor cell apoptosis which is arsenic; all-trans, 9-cis or 13-cis retinoic acid; or 4 allopurinol-l-ribonucleoside |
| 06/03/2008 | US7381706 Gonadotropin-releasing hormone, precursor peptides thereof and genes encoding the same |
| 06/03/2008 | US7381705 Inhibitors of hepatitis C virus |
| 06/03/2008 | US7381704 Methods for use of short bioactive peptides |
| 06/03/2008 | US7381703 Aplidine for multiple myeloma treatment |
| 06/03/2008 | US7381702 Methods of treating diabetes mellitus |
| 06/03/2008 | US7381701 Compositions and methods for treating conditions related to ephrin signaling with cupredoxins |
| 06/03/2008 | US7381700 with botulinum toxin |
| 06/03/2008 | US7381699 Reagents and methods for smooth muscle therapies |
| 06/03/2008 | US7381698 Secretin; rapid and/or complete resolution; reduced side effects |
| 06/03/2008 | US7381560 Administering a chimeric anti-CD20 antibody; hybridomas; monoclonal antibodies |
| 06/03/2008 | US7381534 Immunoglobulin binding immunogenic polypeptide of given sequence; test kits for allergy detection |
| 06/03/2008 | US7381528 Methods for detection of mutations in myostatin variants |
| 06/03/2008 | US7381523 Methods for identifying compounds for treating diabetes mellitus |
| 06/03/2008 | US7381522 IDENTIFYING AN ALLOSTERIC MODULATOR/ANTAGONIST OF G-PROTEIN COUPLED RECEPTORS FOR TREATMENT OF METABOLIC DISORDERS and diseases that have been linked to overactive GPCRs, because traditional neutral-antagonists will not block abnormal ligand-independent activity of these receptors |
| 06/03/2008 | US7381413 Methods and products related to metabolic interactions in disease |
| 06/03/2008 | US7381411 Preventing influenza virus cell binding; schizophrenia; diagnosing chronic viral disease associated with cancer development |
| 06/03/2008 | US7381404 Treatment for dry macular degeneration |
| 06/03/2008 | CA2467964C Composition of estrogen and other hormones with ascorbate, lysine, proline and other substances |
| 06/03/2008 | CA2368186C Use of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors for the manufacture of a medicament for the treatment of diabetic neuropathy |
| 06/03/2008 | CA2313024C Pharmaceutical compositions containing an omega-3 fatty acid oil |
| 06/03/2008 | CA2279846C Engineered protein kinases which can utilize modified nucleotide triphosphate substrates |
| 06/03/2008 | CA2263184C Methods and compositions for increasing the anaerobic working capacity in tissues |
| 06/03/2008 | CA2261018C Treatment and diagnosis of cancer |
| 06/03/2008 | CA2244664C Composition comprising interleukin-1 inhibitor and controlled release polymer |
| 06/03/2008 | CA2243633C Isolated polypeptide for the skin and its use |
| 06/03/2008 | CA2195528C Denervated muscle kinase (dmk), a receptor of the tyrosine kinase super family |
| 06/03/2008 | CA2186269C Wound healing |
| 06/03/2008 | CA2178144C Stabilized aqueous liquid preparations of blood coagulation factor xiii |
| 06/03/2008 | CA2122596C Treatment of neurological conditions by an interleukin-1 inhibiting compound |
| 06/03/2008 | CA2106978C Compositions and methods for treating small cell and nonsmall cell lung cancers |
| 05/31/2008 | WO2007059955A2 Agent for reducing the useable calorie content of food and for therapeutic reduction of weight, in particular for use in the case of adiposity (obesity) |
| 05/31/2008 | CA2669247A1 Agent for reducing the useable calorie content of food and for therapeutic reduction of weight, in particular for use in the case of adiposity (obesity) |
| 05/29/2008 | WO2008064264A2 In vivo methods for identifying and screening compounds that modulate calstabin binding to a ryanodine receptor |
| 05/29/2008 | WO2008063808A2 Encapsulated peptide amphiphile nanostructures |
| 05/29/2008 | WO2008063757A2 Use of tight junction agonists for modulation of the blood brain barrier |
| 05/29/2008 | WO2008063639A2 Compositions and methods for preserving cells of the eye |
| 05/29/2008 | WO2008063493A2 Compositions and methods related to toll-like receptor-3 |
| 05/29/2008 | WO2008063315A2 C-TERMINAL DOMAIN TRUNCATION OF MGLUR1α BY CALPAIN AND USES THEREOF |
| 05/29/2008 | WO2008063229A2 Enzymatic debridement therapy for abnormal cell proliferation |
| 05/29/2008 | WO2008063113A1 Cell -penetrating peptides and constructs containing them consisting 15-25 amino acids of tumor supressor protein p14arf or p19arf |
| 05/29/2008 | WO2008062908A1 Method for producing particles and particles |
| 05/29/2008 | WO2008062699A1 Carrier |
| 05/29/2008 | WO2008062481A2 Formulations of peg-interferon alpha conjugates |
| 05/29/2008 | WO2008062232A1 Depsipeptides and their therapeutic use |
| 05/29/2008 | WO2008062201A1 Depsipeptides and their therapeutic use |
| 05/29/2008 | WO2008062147A1 ILT-2 (LIRl ) VARIANTS WITH INCREASED AFFINITY FOR MHC CLASS I MOLECULES |
| 05/29/2008 | WO2008062110A2 Cosmetic and/or pharmaceutical composition containing at least one peptide as the active ingredient and use of said peptide |
| 05/29/2008 | WO2008061939A1 Recombinant modified vaccinia virus ankara (mva)-based vaccine for the avian flu |
| 05/29/2008 | WO2008061563A1 Peptides for the treatment of multiple sclerosis |
| 05/29/2008 | WO2008061377A1 Novel receptor for cd40l and uses thereof |
| 05/29/2008 | WO2008061355A1 Glp-1 depot systems, and methods of manufacture and uses thereof |
| 05/29/2008 | WO2008061303A1 Method of treatment and prophylaxis |
| 05/29/2008 | WO2008061299A1 Method of treating diabetes |
| 05/29/2008 | WO2008040360A3 Use of hypothermia inducing drugs to treat ischemia |
| 05/29/2008 | WO2008034615A3 Device for removing blood clots from blood vessels |
| 05/29/2008 | WO2008019417A3 Treatment of ocular diseases |
| 05/29/2008 | WO2008019187A9 Detecting and treating dementia |
| 05/29/2008 | WO2007149334A3 Vegf antagonist formulations suitable for intravitreal administration |
| 05/29/2008 | WO2007143161A3 Use of proteins and peptides of the tgf-beta superfamily for purification and therapeutic methods |
| 05/29/2008 | WO2007141309A3 Stabilized insulin-like growth factor polypeptides |
| 05/29/2008 | WO2007113665A3 Polymerized solid lipid nanoparticles for oral or mucosal delivery of therapeutic proteins and peptides |
| 05/29/2008 | WO2007106884A3 Methods of treating muscular wasting diseases using nf-kb activation inhibitors |
| 05/29/2008 | WO2007074456A3 Inhibition of cxcr4 and/or cell motility by phenylalanine, cysteine or peptides containing said aminoacids |
| 05/29/2008 | WO2007005300A3 Treatment of dry eye |
| 05/29/2008 | WO2006137597A9 Novel physiological substance nesfatin, substance relevant thereto, and use of the substances |
| 05/29/2008 | US20080125498 Treatment of neurodegenerative diseases and conditions using par1 antagonists |
| 05/29/2008 | US20080125457 O-methylated rapamycin derivatives for alleviation and inhibition of lymphoproliferative disorders |
| 05/29/2008 | US20080125395 Compositions and methods for the treatment of skin |
| 05/29/2008 | US20080125391 administering to a mammal harboring a tumor which expresses HALRs, a Sindbis virus vector to treat the tumor, and the vector has not been modified to target a tumor-specific cellular determinant, has a preferential affinity for HALRs, a Sindbis virus E2 HALR binding domain; ganciclovir; gene therapy |
| 05/29/2008 | US20080125390 Methods for Modulating Immune and Inflammatory Responses |
| 05/29/2008 | US20080125376 Viricide against hepatitis virus; pyrrole derivatives as, for example, 3-acetyl-4,5-dimethyl-2-pyrrole carboxylic acid |
| 05/29/2008 | US20080125375 Peptide like compounds for treating coronavirus or aviviridae virus; severe acute respiratory distress syndrome |
| 05/29/2008 | US20080125374 Gd3-mimetic peptides |
| 05/29/2008 | US20080125373 Motoneuronotrophic factors (MNTF); nerve growth factors; spinal cord injuries; neurodegenerative diseases |
| 05/29/2008 | US20080125372 Biologically Active Peptide Vapeehptllteaplnpk Derivatives |
| 05/29/2008 | US20080125371 Specific antagonists for glucose-dependent insulinotropic polypeptide (GIP) |
| 05/29/2008 | US20080125370 Preventing grampositive bacterial infection via upregulation of interleukin expression and down-regulating pro-inflammatory cytokine expression; sepsis |
| 05/29/2008 | US20080125369 Soluble t cell receptors |
| 05/29/2008 | US20080125368 Determining angiogenin levels to aid in assessment of peritoneal membrane injury or complications of peritoneal dialysis; drug screening |
| 05/29/2008 | US20080125367 Agents for treatment of HCV and methods of use |
| 05/29/2008 | US20080125366 Insecticidal proteins derived from Bacillus Thuringiensis |
| 05/29/2008 | US20080125365 Fibronectins; inflammation |
| 05/29/2008 | US20080125364 Increasing formation of tight junctions by modulating occludin activity of transformed cells (induced by RAF1) |
| 05/29/2008 | US20080125363 Nonantigenic; biochemical conjugation; polyoxyethylene glycol; anticancer agents |
| 05/29/2008 | US20080125362 Method of screening compound preventing cells from infection with Hepatitis C virus (HCV) |
| 05/29/2008 | US20080125361 Stable Formulations Of Peptides |
| 05/29/2008 | US20080125360 Use of polypeptide YY (PYY) administered parenterally to treat pain, abdominal pain, constipation and/or diarrhea from irritable bowel syndrome, functional dyspepsia; use in combination with antidepressants or antiemetics |
| 05/29/2008 | US20080125359 Antimicrobial peptides and methods of identifying the same |
| 05/29/2008 | US20080125358 Methods for Chk2 inhibitor patient selection |
| 05/29/2008 | US20080125357 Novel peptide ligand to the orphan G-protein coupled receptor ChemerinR; Prochemerin and Chemerin amino acid sequences; use in diagnosis and immunotherapy of a disease including tumors |
| 05/29/2008 | US20080125356 Stable Growth Hormone Liquid Formulation |
| 05/29/2008 | US20080125355 Endogenous Peptide and Active Subfragments Thereof |
| 05/29/2008 | US20080125354 With triple helix and/or poly-proline type II transition state analog phosphorus based inhibitor comprising a phosphonamide, phosphinic peptide or phosphonate ester; e.g. (R,S)-2-Isopropyl-3-((1-(N-(9-Fluorenylmethoxycarbonyl)amino)-methyl)-adamantyloxyphosphinyl)propanoic acid; antitumor agents |
| 05/29/2008 | US20080125353 Use of Exendins and Agonists Thereof for the Treatment of Gestational Diabetes Mellitus |
| 05/29/2008 | US20080125352 Unique Integrin Binding Site in Connective Tissue Growth Factor |